Iovance Biotherapeutics, Inc.
DE ˙ DB ˙ US4622601007
€3.31 ↓ -0.17 (-4.89%)
2026-06-04
주가
SecurityDE:2LB / Iovance Biotherapeutics, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership0 shares
Ownership 0.00%
Vanguard Group Inc ownership in 2LB / Iovance Biotherapeutics, Inc.

2026-03-27 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Iovance Biotherapeutics, Inc. (DE:2LB). This represents 0.0 percent ownership of the company. In their previous filing dated 2025-07-29 , Vanguard Group Inc had reported owning 25,076,472 shares, indicating a decrease of -100.00 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-03-27 2026-03-27 13G/A 25,076,472 0 -100.00 0.00 -100.00
2025-07-29 2025-07-29 13G/A 22,812,820 25,076,472 9.92 7.50 -15.82
2024-02-13 2024-02-13 13G/A 14,463,082 22,812,820 57.73 8.91 -2.73
2023-02-09 2023-02-09 13G/A 12,197,787 14,463,082 18.57 9.16 17.89
2022-02-10 2022-02-10 13G/A 11,865,382 12,197,787 2.80 7.77 -3.96
2021-02-10 2021-02-10 13G/A 10,853,129 11,865,382 9.33 8.09 -5.93
2020-02-11 2020-02-11 13G 10,853,129 8.60

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 27,207,079 3,148,096 13.08 74,275 42.27 0.0011
2025-11-07 2025-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 24,058,983 -1,017,489 -4.06 52,208 21.04 0.0008
2025-08-11 2025-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 25,076,472 -2,701,306 -9.72 43,132 -53.37 0.0007
2025-05-09 2025-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 27,777,778 243,438 0.88 92,500 -54.60 0.0017
2025-02-11 2024-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 27,534,340 220,373 0.81 203,754 -20.56 0.0035
2024-11-13 2024-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 27,313,967 1,363,323 5.25 256,478 23.23 0.0046
2024-08-13 2024-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 25,950,644 1,035,344 4.16 208,124 -43.64 0.0040
2024-05-10 2024-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 24,915,300 2,102,480 9.22 369,245 99.09 0.0073
2024-03-11 2023-12-31 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 22,812,820 669,350 3.02 185,468 84.08 0.0041
2024-02-14 2023-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 22,812,820 669,350 185,468 0.0041
2023-12-18 2023-09-30 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 22,143,470 1,748,082 8.57 100,753 -29.83 0.0025
2023-11-14 2023-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 22,143,470 1,748,082 100,753 0.0025
2023-08-14 2023-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 20,395,388 6,855,259 50.63 143,584 73.56 0.0034
2023-07-14 2023-03-31 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 13,540,129 -922,953 -6.38 82,730 -10.48 0.0021
2023-05-15 2023-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 13,540,129 -922,953 82,730 0.0021
2023-02-10 2022-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 14,463,082 209,328 1.47 92,419 -32.32 0.0025
2022-11-14 2022-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 14,253,754 890,727 6.67 136,551 -7.44 0.0040
2022-08-12 2022-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 13,363,027 1,021,374 8.28 147,529 -28.21 0.0041
2022-05-13 2022-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 12,341,653 143,866 1.18 205,489 -11.75 0.0049
2022-02-14 2021-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 12,197,787 268,798 2.25 232,856 -20.84 0.0053
2021-11-12 2021-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 11,928,989 -307,422 -2.51 294,169 -7.61 0.0073
2021-08-13 2021-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 12,236,411 182,924 1.52 318,392 -16.57 0.0079
2021-05-14 2021-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 12,053,487 188,105 1.59 381,614 -30.69 0.0103
2021-02-12 2020-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 11,865,382 86,855 0.74 550,555 41.99 0.0160
2020-11-16 2020-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 11,778,527 -449,943 -3.68 387,750 15.52 0.0128
2020-08-14 2020-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 12,228,470 1,099,259 9.88 335,670 0.76 0.0119
2020-05-15 2020-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 11,129,211 276,082 2.54 333,153 10.90 0.0142
2020-02-14 2019-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 10,853,129 324,949 3.09 300,415 56.78 0.0102
2019-11-14 2019-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 10,528,180 2,036,339 23.98 191,613 -7.98 0.0071
2019-08-14 2019-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 8,491,841 2,688,963 46.34 208,220 277.31 0.0078
2019-05-15 2019-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 5,802,878 23,809 0.41 55,185 7.90 0.0022
2019-02-14 2018-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 5,779,069 1,730,287 42.74 51,145 12.28 0.0023
2018-12-13 2018-09-30 13F/A-2 IOVANCE BIOTHERAPEUTICS COM 462260100 4,048,782 302,649 8.08 45,550 -5.01 0.0018
2018-11-23 2018-09-30 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 4,048,782 0 45,550 0.0018
2018-11-14 2018-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 4,048,782 302,649 45,550
2018-08-14 2018-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 3,746,133 470,277 14.36 47,950 -13.39 0.0020
2018-05-15 2018-03-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 3,275,856 523,633 19.03 55,362 151.44 0.0024
2018-02-14 2017-12-31 13F IOVANCE BIOTHERAPEUTICS COM 462260100 2,752,223 245,384 9.79 22,018 13.33 0.0010
2017-11-14 2017-09-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 2,506,839 314,615 14.35 19,428 20.57 0.0009
2017-08-24 2017-06-30 13F/A-1 IOVANCE BIOTHERAPEUTICS COM 462260100 2,192,224 -52,975 -2.36 16,113 -3.66 0.0008
2017-08-11 2017-06-30 13F IOVANCE BIOTHERAPEUTICS COM 462260100 2,192,224 16,113
2017-05-12 2017-03-31 13F LION BIOTECHNOLOGIES COM 53619R102 2,245,199 26,039 1.17 16,726 8.45 0.0009
2017-02-14 2016-12-31 13F LION BIOTECHNOLOGIES COM 53619R102 2,219,160 73,801 3.44 15,423 -12.65 0.0009
2016-11-14 2016-09-30 13F LION BIOTECHNOLOGIES COM 53619R102 2,145,359 523,549 32.28 17,656 34.41 0.0010
2016-08-10 2016-06-30 13F LION BIOTECHNOLOGIES COM 53619R102 1,621,810 -4,136 -0.25 13,136 59.05 0.0008
2016-05-13 2016-03-31 13F LION BIOTECHNOLOGIES COM 53619R102 1,625,946 115,390 7.64 8,259 -29.17 0.0005
2016-02-08 2015-12-31 13F LION BIOTECHNOLOGIES COM 53619R102 1,510,556 79,600 5.56 11,661 41.48 0.0008
2015-11-12 2015-09-30 13F/A-1 LION BIOTECHNOLOGIES COM 53619R102 1,430,956 161,723 12.74 8,242 -29.19 0.0003
2015-11-12 2015-09-30 13F/A-1 LION BIOTECHNOLOGIES COM 53619R102 1,430,956 161,723 8,242 0.0003
2015-08-13 2015-06-30 13F LION BIOTECHNOLOGIES COM 53619R102 1,269,233 995,477 363.64 11,639 251.10 0.0008
2015-05-15 2015-03-31 13F/A-1 LION BIOTECHNOLOGIES COM 53619R102 273,756 273,756 3,315 0.0002
2015-05-14 2015-03-31 13F LION BIOTECHNOLOGIES COM 53619R102 273,756 3,315 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.